Guardant Health is actively collecting real-world validation data for its multi-cancer detection blood test, according to a report from 360Dx. The company is gathering this information to support the test’s performance in clinical practice.
The effort focuses on assessing how the test works outside of controlled trial settings. By using real-world data, Guardant Health aims to evaluate the test’s accuracy and utility in broader patient populations, 360Dx reports.
This type of validation is important for multi-cancer detection tests, which are designed to screen for multiple cancer types from a single blood sample. Real-world data can help show whether a test performs as well in everyday use as it does in studies. The approach also allows companies to track outcomes over time and across diverse groups of patients.
Other recent coverage has highlighted both the promise and the limitations of such tests. For example, a separate report noted that doctors in Omaha have warned that a newly FDA-approved cancer test has limits. That reporting underscores the need for ongoing data collection to clarify how these tests should be used.
Guardant Health’s move to gather real-world evidence suggests the company is looking to strengthen its case for the test’s clinical value. The data could inform future regulatory submissions or help guide doctors on when to use the test.
What to watch next: whether Guardant Health releases interim results from its real-world data collection and how those findings might shape the test’s adoption.
